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ABSTRACT

Colostrum is the first milk produced by mammals within a 24 to 72 hour period
after parturition. Bovine colostrum is sold commercially as a nutraceutical product and
its manufacturers purport numerous health benefits of the product for treating
gastrointestinal disorders, respiratory tract disorders, viral and bacterial infections, and
promoting tissue repair.
Four commercially available colostrum products, two whey, and one non-fat dry
milk were obtained on separate days. These products were analyzed for fat, protein, ash,
moisture and dry matter content. One colostrum product did not adhere to label claims in
that it contained a mean of 19.1% fat whereas the label claimed the product to be fat free.
One whey sample was slightly above 0.5% fat whereas the label claimed the product was
fat free.
Immunoglobulin content was analyzed on the dried dairy supplement products
using a single radial immunodiffusion method. Results indicated that all four colostrum
products contained less immunoglobulin G (IgG) than label or corresponding company
website claims.
Bacterial enumeration of dried colostrum products was extremely difficult in
methodology due to inability to distinguish white bacterial colonies from white clumps of
the dried dairy products. Various experimental techniques were attempted in order to
overcome these hurdles; however, a successful methodology was not developed.
Bacterial identification was accomplished on isolates using 16S rRNA analysis to
determine the microbial population present in the dried dairy dietary supplements.
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Results indicated no lactic acid bacterial genera were identified but several species of
primarily Bacillus and Pseudomonas were identified.
Studies to determine the antimicrobial activity of the dried dairy products were
conducted using disk diffusion and well diffusion assays against Escherichia coli (ATCC
25922) and Staphylococcus aureus (ATCC 25909). Results indicated no antimicrobial
activity from any of the dairy products.
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LITERATURE REVIEW
Introduction
Colostrum is the nutrient-rich, first secretion produced by mammals within 24 to
72 hours after parturition.

Colostrum contains various proteins, carbohydrates, fats,

vitamins, and minerals that are essential for the diet of a developing mammalian neonate.
Colostrum also includes bioactive constituents such as immunoglobulins, antimicrobial
peptides, and growth factors. These bioactive components are not just restricted to
colostrum, but are found in a lesser degree in milk and whey products.
Bovine colostrum is commonly used as a raw material to produce
immunoglobulin-rich, bioactive commercial products which may sell for up to $250-300
per pound. Bovine colostrum contains nutrients that cannot cross the placental barrier to
the calf during pregnancy and, therefore, must be delivered to the newborn following the
birthing process. It is sold as a dietary supplement for therapeutic uses in adult humans
due to this rich nutrient content.

However, there is a lingering question as to the

efficiency of absorption of colostrum in the adult human intestinal tract. Recent refereed
studies suggest that colostrum and fractions thereof may be useful for treatment of a
variety of health conditions, including gastrointestinal disorders, respiratory tract
disorders, viral and bacterial infections, and tissue repair.

Colostrum as a Dietary Supplement: Historical Perspective
Colostrum is vital to human development through its role in infant health and
nutrition. For many centuries, the benefits of colostrum were debated. In India, during
the fourth century B.C., ritual practices dictated that infants were fed a mixture of honey,
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clarified butter, plant juices, and gold dust for the first few days after birth instead of
colostrum (Stuart-MacAdams, 1995). During the first century A.D., Soranus of Ephesus,
advised parents to feed newborn children boiled honey and goat‟s milk as a first food
rather than colostrum (Stuart-MacAdams, 1995). He believed that maternal milk was
unhealthy during the first 20 days after birth, so a wet nurse was often used. However,
Soranus advised that a child should only be breast fed for several months, but then the
child‟s principal food should be the milk of other animals like camels or cows (StuartMacAdams, 1995).
By the end of the seventeenth century A.D and the beginning of the eighteenth
century A.D., the beliefs about colostrum began to slowly change (Stuart-MacAdams,
1995). During the eighteenth century, the English physicians William Cadogen and
William Moss advocated giving colostrum to an infant after birth. Cadogen and Moss
noted that replacement infant foods were correlated with abdominal distress and/or
gastrointestinal infections (Stuart-MacAdams, 1995). In 1892, the German scientist Paul
Ehrlich confirmed that antibodies are transferred to a newborn animal by colostrum
(Stuart-MacAdams, 1995). This finding established the immunological importance of
colostrum in mammalian neonates.
Ayurvedic physicians and naturopathic healers have used bovine colostrum for
thousands of years for medical treatment of certain skin and eye infections (StuartMacAdams, 1995). In Sweden and The Netherlands, a traditional pudding has been made
from colostrum for centuries; this pudding is used for both celebration and purported
health benefits (Stuart-MacAdams, 1995).
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In 1950, physician Dr. Albert Sabin

discovered that colostrum contained antibodies against polio and recommended at risk
patients consume colostrum (Stuart-MacAdams, 1995).
Current research has indicated that an infant should consume colostrum for the
first few days after birth in order to initiate immunological protection and establish
gastrointestinal microflora balance (Xu et al., 1996). Colostrum delivers its nutrients in a
very concentrated low-volume form. These nutrients are passed to the infant and provide
protection against pathogens as well as assistance with development of the
gastrointestinal tract (Xu et al., 1996).

Since similar biologically active molecules of

human colostrum also are found in bovine colostrum, scientific researchers and
nutraceutical companies are studying the effect of whole and fractionated bovine
colostrum on various human illnesses and for food processing industries.

Bovine Colostrum Harvesting and Processing
Bovine colostrum is sold for use as a nutraceutical product. The concept of a
“nutraceutical” originated in Japan during the 1980s with the development of
“physiologically functional foods” that are considered, by definition, to be “any food or
ingredient that has a positive impact on an individual‟s health, physical performance, or
state of mind, in addition to its nutritive value” (Hardy, 2000).

In 1989, the term

“nutraceutical” was coined by the Foundation for Innovation in Medicine in order to
differentiate nutraceuticals from drugs, medicinal foods, and physiologically functional
foods. The term “nutraceutical” was specifically defined as “any substance that may be
considered a food or part of a food, and provides medical or health benefits, including the
prevention and treatment of disease” (Hayden, 2007). Hardy (2000) further defined
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“nutraceuticals” as “bioactive chemicals derived from foods but taken as supplements at
much higher concentrations than diet alone could provide. They include antioxidants
from fruits and berries, fatty acids found in cold-water fish, and potentially disease
fighting compounds from common spices such as cinnamon and turmeric” (Hardy, 2000).
The concept of a nutraceutical had to be defined in order to differentiate nutraceutical
substances from medical foods in the United States. Medical foods are defined by the
U.S. Food and Drug Administration (FDA) as “formulated to be consumed or
administered internally under the supervision of a physician and which is intended for the
specific dietary management of a disease or condition for which distinctive nutritional
requirements, on the basis of recognized scientific principles, are established by medical
evaluation” (Hardy, 2000). The range of consumer products sold as nutraceuticals and
dietary supplements is broad and often incorrectly categorized. A dietary supplement is
defined as a "product taken by mouth that contains a „dietary ingredient‟ intended to
supplement the diet.” They include “vitamins, minerals, herbs or other botanicals, amino
acids, and substances such as enzymes, organ tissues, glandulars, and metabolites....."
(Food and Drug Administration, 2010). Nutraceuticals were estimated to generate $22.5
billion in consumer sales in the United States in 2006, and sales have increased in recent
years (Hayden, 2007).
Bovine colostrum has many purported health benefits. However, as Moore et al.
(2005) reported, bovine colostrum should be harvested as soon as possible after calving
to maximize colostrum quality. Approximately, 5 - 10 liters of colostrum per milking is
normally obtained from a dairy cow (Moore et al., 2005).
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The typical dairy cow

produces more colostrum than is consumed by the calf and in commercial bovine
colostrum operations, this excess colostrum can be processed for nutraceutical products
(Moore et al., 2005).

In addition to maintaining excellent sanitary conditions, it is

essential to collect bovine colostrum within hours of birth (Moore et al., 2005).
Immunoglobulin (Ig) concentrations in mammary secretions decrease with time after
parturition (Moore et al., 2005). Moore et al. (2005) collected colostrum from randomly
selected quarters at 2, 6, 10, and 14 hours after calving. Colostral IgG concentration from
each sample was determined with radial immunodiffusion. Results revealed that IgG
concentrations rapidly declined with IgG levels measuring at 113, 94, 82, and 76 g/L at 2,
6, 10, and 14 hours, respectively.

Moore et al. (2005) recommended that bovine

colostrum should be harvested within 6 hours of parturition to obtain a high quality
product.
Once bovine colostrum is harvested, it most commonly is dehydrated by either
spraying drying or freeze-drying. Spray-drying allows a liquid product to be atomized
and contacted with a hot gas to instantaneously obtain a powder. In the food industry,
spray-drying decreases water activity to ensure microbiological stability of products,
avoid the risk of chemical and/or biological degradation, reduce the storage and transport
costs, and finally obtain a product with specific properties like instantaneous solubility
(Kudra et al., 2002). Chelack et al. (1993) reported that spray drying bovine colostrum is
conducted at a low temperature, thereby, allowing minimal loss of immunoglobulin
function and quantity (up to 94%).

Although immunoglobulins activity is well

conserved, a disadvantage to spray drying is a 25% loss of total solids from the bovine
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colostrum (Chelack et al., 1993). The spray-drying of bovine colostrum is the same
method used in the manufacture of dried milk. When whole or low fat milk is spraydried, a mixture of lactose and milk proteins are microencapsulated by milk fat. This
outer layer imparts protection against oxidation. Chelack et al. (1993) hypothesized that
the butterfat in spray dried bovine colostrum undergoes a similar microencapsulation
process.

Commercially, spray-dry processing of colostrum is up to 2.5 times less

expensive than freeze-dry processing (Chelack et al., 1993).
Chelack et al. (1993) reported the lengthy process of freeze-drying or
lyophilization is the most effective method for preservation of immunoglobulin function
and minimal loss of total solids.

The process of freeze drying is widely used for

pharmaceuticals to improve long-term storage of unstable drugs (Chelack et al., 1993).
Freeze drying utilizes low temperatures, along with rapid dehydration of a liquid product.
This technique allows for a reduction of protein denaturation in the product as compared
to spray drying. According to Elfstrand et al. (2002), the process of freeze-drying bovine
colostrum concentrate decreased the amount of native IgG1,IgG2 and IgA by 25%
compared to colostrum whey. In this study, (Elfstrand et al., 2002), colostrum was
defined as pooled product collected in three time intervals from 0 to 50 hours postpartum;
colostrum whey was defined as a pooled colostrum product collected from seven time
intervals from 0 and 80 hours postpartum with additional heat treatment and
microfiltration prior to freeze-drying. The freeze-dried colostrum whey had decreased
IgG2 and IgA of 35–40%, while IgG1 only was reduced by 17%. Elfstrand et al. (2002)
also revealed the highly sensitive nature of IgM after freeze-drying of colostrum

6

concentrate and colostrum whey. After the freeze-drying processing of colostrum whey,
only 2% of IgM remained, whereas IgM could not be detected in colostrum concentrate
after freeze-drying (Elfstrand et al., 2002). Thus, IgM seems to be the most sensitive of
the immunoglobulins during processing of bovine milk products. Elfstrand et al. (2002)
also demonstrated that freeze-drying reduced the amount of the immunomodulating agent
known as transforming growth factor-beta 2 (TGF-β2), and the hormone known as
insulin-like growth factor 1 (IGF-1) in colostrum concentrate by 30%. A minor reduction
also was observed in the freeze-dried colostrum whey (Elfstrand et al., 2002). The same
researchers hypothesized the layers of fat, casein, lactose and salts play a protective role
for immunoglobulins and TGF-β2 in colostrum concentrate and whey during freezedrying. Due to the negative effects of freeze drying and spray-drying on the content of
bioactive substances in colostrum, it is important to note how the bovine colostrum is
processed in order to retain the activity of these influential bioactive components in milk.

Bovine Colostrum Bioactive Components and Fractions
Lactoferrin was initially isolated from cow‟s milk in 1939 by Sørensen and
Sørensen (Conesa et al., 2010). It was considered to be a transferrin-like glycoprotein
(Lőnnerdal et al., 1995). Lactoferrin is defined as an iron binding glycoprotein that

consists of a single polypeptide chain with a molecular mass of 80 kDa (Lőnnerdal et al.,
1995). The polypeptide structure of lactoferrin is composed of two homologous domains
hypothesized to have been formed by intragenic duplication (Lőnnerdal et al., 1995).
These two domains bind to one ferric cation and one carbonate anion, along with one
glycosylated site where N-linked glycan residues attach (Lőnnerdal et al., 1995).
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Lactoferrin can be found mostly in colostrum and milk, as well as tears, saliva, mucous,
and blood (Pakkanen et al., 1997).

Lactoferrin is expressed and secreted by the

secondary granules of polymorphonuclear neutrophils (Pakkanen et al., 1997).
Antimicrobial activity has been documented in lactoferrin inhibition of Gram-negative
and Gram positive bacteria, as well as yeasts, fungi, parasites, and viruses. Additionally,
multiple studies have reported that lactoferrin appears to be involved in antiinflammatory and other immune responses. It appears that two different mechanisms
involving two separate domains of the protein contribute to the antimicrobial functions of
lactoferrin (van Hooijdonk et al., 2000). The first mechanism is a bacteriostatic effect
related to the high iron binding affinity of the protein that deprives iron-requiring bacteria
of this essential growth nutrient (van Hooijdonk et al., 2000). The second antibacterial
property of lactoferrin is due to a direct bactericidal function within the protein (van
Hooijdonk et al., 2000). The antimicrobial activity of lactoferrin was demonstrated
against Streptococcus mutans, Listeria monocytogenes, Shigella dysenteria, Salmonella
typhimuium, Bacillus subtilis, Bacillus (Geobacillus) stearothermophilis, and Vibrio
cholera in various studies (Pakkanen et al., 1997).
Lassiter et al. (1987) suggested a direct bactericidal method of inhibiting growth
of bacteria via interaction of lactoferrin with lipopolysaccharide (LPS) of the Gramnegative bacterial membrane of E. coli.

However, addition of calcium (Ca2+) and

magnesium ions (Mg2+) impaired lactoferrin inhibition of bacteria. The presence of Ca2+
ions also inhibited the ability of lactoferrin to increase the susceptibility of E. coli to the
antibiotic rifampicin (Lassiter et al.,1987). Lactoferrin binds to porin molecules in the
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outer membrane of E. coli and Salmonella typhimurium causing permeability changes
(Lassiter et al., 1987). Lactoferrin is active at a neutral pH, and in the presence of
bicarbonate ions (Pakkanen et al., 1997) which are both conditions in the lumen of the
intestine; these conditions allow lactoferrin to exercise antimicrobial activity (Lassiter et
al., 1987).
Lactoperoxidase is a basic glycoprotein containing a heme group with Fe3+ that
catalyzes the oxidation of thiocyanate in the presence of hydrogen peroxide producing a
toxic intermediary oxidation product (Pakkanen et al., 1997). This particular product
inhibits bacterial metabolism via oxidation of essential sulfhydryl groups in proteins. This
single peptide chain of about 612 amino acids contains 15 half-cysteines, 4 Nglycosylation sites, and a high affinity calcium binding site (Kussendrager et al., 2000).
Commonly, lactoperoxidase is considered to be a major antibacterial enzyme in
colostrum. It is known that this enzyme protects the lactating mammary gland from
bacterial infections (Pakkanen et al., 1997). Both Gram positive and Gram negative
microbes have been found to be susceptible to lactoperoxidase including Pseudomonas
aeruginosa, Salmonella typhimurium, Listeria monocytogenes, Streptococcus mutans,
and Staphylococcus aureus (Pakkanen et al., 1997). Lactoperoxidase and lactoferrin can
have an additive effect on the inhibition of microbes, but they are not synergistic,
particularly with Streptococcus mutans (Pakkanen et al., 1997).
Lysozymes are antibacterial, lytic enzymes discovered by Alexander Fleming in
1922 from his nasal mucosal passages (Pakkanen et al., 1997). Lysozymes are present in
multiple mammalian bodily fluids, particularly colostrum. The lysozymes degrade the
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peptidoglycan layer of the bacterial cell wall and result in the lysis of the bacterial cells.
Lysozymes contain cationic and hydrophobic qualities that interact with the bacterial
membranes to lyse bacterial cells (Pakkanen et al., 1997). Milk and colostrum lysozymes
are bacteriocidal against numerous Gram positive and Gram negative microbes
(Pakkanen et al., 1997). Yamauchi et al. (1993) reported lactoferrin synergistically
enhances the antimicrobial activity of milk and colostrum lysozymes against E. coli.
Growth factors are present in both milk and colostrum as a mammalian cell
growth stimulator. Klagsbrun and Neumann (1979) demonstrated the stimulation of
mouse fibroblasts with the addition of bovine colostrum. The most prevalent growth
factors in bovine colostrum are the insulin-like growth factors (IGF-1 and IGF-2). IGF-1
and IGF-2 are heat and acid-stable growth factors that consist of approximately 7.6 kDa
single-chain polypeptides (Pakkanen et al., 1997).

IGF-1 and IGF-2 exist in many

mammalian body cells to stimulate glucose uptake, the synthesis of glycogen, protein,
RNA, DNA, and lipids (Pakkanen et al., 1997).

IGFs in colostrum and milk originate

from blood circulation and are not due to local synthesis in the mammary tissues
(Pakkanen et al., 1997). Type I and II IGF receptors have been reported to be present in
bovine mammary tissue and on intestinal epithelial cells leading to many questions as to
the function of IGFs in colostrum and milk. Shamay et al. (1988) demonstrated that
dietary based IGF-1 from milk based products are a strong stimulator of mitogenesis and
galactopoesis of bovine mammary cells. Xu et al. (1994) and Baumrucker et al. (1994)
reported that dietary bovine colostrum stimulated intestinal epithelial cells in the
gastrointestinal tract of newborn piglets and calves. Baumrucker et al (1992) reported
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that specifically orally-administered IGF-1 promoted the growth of the small intestine of
newborn pigs.

Baumrucker and Blum et al. (1993) demonstrated that that IGF-1

suppressed insulin secretion and stimulated prolactin secretion. However, research on the
effects of dietary IGF-2 from colostrum and milk products has not been well-described in
the literature.
Transforming growth factors beta (TGF-β1 and TGF-β2) are highly pleiotrophic
peptide growth factors with multiple functions. The two types of TGF- β stimulated cell
growth in connective tissues, while inhibiting cell growth of lymphocytes and epithelial
cells in other tissues (Pakkanen et al., 1997). The TGF- β substances are involved in
embryogenesis, tissue repair, formation of bone and cartilage, and modulation of the
immune system (Pakkanen et al., 1997). TGF-β2 is the predominant TGF- β found in
milk-based products, and its whole amino acid sequence is identical to the sequence of
TGF- β2 found in humans. The function of the two types of TGF- β from colostrum and
milk products is largely unknown, but Cox and Bürk (1991) suggested that TGF- β1 and
TGF- β2 may be mediators of mucosal immunity and gut epithelial differentiation in a
neonate mammal. Several studies have indicated that TGF- β1 and TGF- β2 increase the
production of IgG and IgA (Pakkanen et al., 1997). Additionally, McGee et al. (1991)
stated that TGF- β stimulated the secretory component in rat epithelial cells, which is
primarily responsible for transferring polymeric IgA into the intestinal lumen. It was
suggested that IgA plays a major role in the immunological defense systems of mucous
membranes in the gut against pathogenic microbes (McGee et al.., 1991); this is
particularly important with TGF- β in colostrum or milk based products.
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Bovine colostrum is a potent source of immunoglobulins. The absorption of
immunoglobulins is essential to the development of passive immunity in calves after birth
for protection against enteric and respiratory infections.

Initially, calves absorb the

maternal immunoglobulins that are concentrated in the colostrum. The colostral
immunoglobulins are transferred from the lumen of the calf‟s intestine into the blood
circulation (Pakkanen et al., 1997). IgG1 is transported from the blood circulatory system
in the cow by an active receptor-mediated transfer across the mammary gland epithelium
in the cow. Once the IgG1 diffuses across the vascular endothelium, the IgG1 binds to
specific IgG1-Fc receptors on the basal membrane of the mammary secretary epithelium.
The IgG1 is then transferred through the epithelial cells that secrete the molecules into the
colostrum, prior to suckling.
The total immunoglobulin concentration present in bovine colostrum is
approximately a hundred fold higher than in milk. Commercially available colostrum
products available for calves and humans usually contain low amounts of
immunoglobulins as compared to natural colostrum (Pakkanen et al., 1997, Haines et al.,
1990). In fresh colostrum, it is noted that IgG1 is the predominant immunoglobulin while
IgM, IgA, and IgG2 are present in much lower levels (Table 1) (Mach and Pahud, 1971).

Table 1: The Concentration of Immunoglobulins in Fresh Colostrum and Normal Milk
(Mach and Pahud, 1971)
Immunoglobulin
Colostrum
Normal Milk
(gL-1)
(gL-1)
IgG1
52.0-87.0
0.31-0.40
IgG2
1.6-2.1
0.03-0.08
IgM
3.7-6.1
0.03-0.06
IgA
3.2-6.2
0.04-0.06
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In the newborn calf, the immunoglobulins are absorbed from the colostrum into
blood circulation through a non-selective macromolecular transport system across the
small intestinal epithelium. This non-selective absorption of immunoglobulins in calves
only occurs for 24 to 36 hours after birth (Pakkanen et al., 1997).

Experimental and Clinical Uses of Bovine Colostrum
Throughout history, bovine colostrum was utilized to treat numerous disorders
and illnesses. The beneficial and medicinal nature of bovine colostrum was well-known
by ancient cultures; however, it is only until recently that scientific research has begun
purporting the experimental and clinical uses of bovine colostrum and its bioactive
components. In 1986, Tzipori et al. studied use of hyperimmune bovine colostrum to
reduce the symptoms of a Cryptosporidium parasitic infection in a 3 year old, male
patient with hypogammaglobulinemia (Tzipori et al., 1986). The patient was treated with
an infusion of hyperimmune bovine colostrum produced against the parasite antigen. The
treatment appeared to stop the diarrheal symptoms due to the cryptosporidiosis (Tzipori
et al., 1986).
In 1993, Plettenberg et al. conducted a study on 25 male patients infected with
human immunodeficiency virus (HIV) with chronic diarrhea to determine the efficiency
of the bovine colostrum product Lactobin®. Lactobin® is a standardized concentrate
produced from New Zealand bovine colostrum by Biotest Pharma GmbH in Dreieich,
Germany for clinical uses (Plettenberg et al., 1993).

Since cows are natural hosts of

pathogenic Cryptosporidium, the Cryptosporidium-specific antibodies are naturally
present in the Lactobin® preparation. Plettenberg et al. (1993) demonstrated a remission

13

of Cryptosporidium-related diarrheal symptoms in 43% of the studied HIV patients.
However, no control group was included in the study.
Additionally, Jenkins et al. (1999) studied hyperimmune bovine colostrum,
specific for the recombinant Cryptosporidium parvum antigen, in dexamethasone (DEX)treated, immunosuppressed mice. Pre-partum cows were immunized by injecting the
DNA directly into the mammary gland with recombinant plasmid DNA encoding the
Cryptosporidium parvum CP15/60 antigen (Jenkins et al., 1999). The bovine colostrum
was collected after parturition and utilized to examine the presence of passive immunity
against Cryptosporidium parvum through oral administration in immunosuppressed adult
inbred mice (Jenkins et al., 1999). Jenkins et al. (1999) demonstrated that the infected
mice receiving immune colostrum had a 50% reduction in the presence of intestinal
Cryptosporidium parvum, in comparison to immunocompromised mice receiving nonimmunized, control colostrum.
In 1998, Sarker et al. further revealed the beneficial nature of hyperimmune
bovine colostrum by demonstrating a decrease in diarrheal symptoms and a quicker
clearance of rotavirus in infected children in comparison to a placebo group. Although
bovine colostrum contains antibodies against enteric pathogens, the level of antibodies is
often too low to provide treatment against certain infections (Sarkar et al., 1998).
Therefore, Sarkar et al. (1998) utilized hyperimmune bovine colostrum, which contained
high levels of antibodies against the four human serotypes of rotavirus. As mentioned
previously, the hyperimmune bovine colostrum appeared to be an effective treatment
against rotavirus in moderate to severe cases in infected children.

14

In addition to providing treatment for viral and parasitic infections, bovine
colostrum also has been found by many scientific studies to provide protection or
eradicate bacterial infections.

In 1977, Corley et al. studied the effect of bovine

colostrum on Escherichia coli O55:B5:H7 transepithelial migration in neonatal calf
intestine in tissue culture.

One hour after colostrum ingestion, young calves were

provided with E. coli suspended in saline, E. coli suspended in bovine colostrum, or E.
coli and bovine colostrum in saline. Intestinal tissues of the calves were then collected 24
hours after treatment (Corley et al., 1997).

Corley et al. (1977) reported E. coli

O55:B5:H7 was reduced when dispensed with bovine colostrum. Also, transepithelial
migration of E. coli O55:B5:H7 ceased when colostrum was administered prior to E. coli
O55:B5:H7 treatment. In addition to animal studies, human and tissue culture studies
have revealed the valuable nature of bovine colostrum.
In 1998, Bitzan et al. reported bovine colostrum concentrate (100 mg/mL) caused
in vitro inhibition of Helicobacter pylori binding to purified lipid receptors from gastric
mucosal and epithelial cells.

Receptors studied included the phospholipid

phosphatidylethanolamine and the neutral glycolipids gangliotetraosylceramide and
gangliotetrasykeramide using thin layer chromatography overlay. Bitzan et al. (1998)
demonstrated the potential anti-adhesive, anti-infectivity properties of bovine colostrum
for H. pylori with selected lipid receptors in vitro. This finding was significant since a
critical point in the pathogenesis of H. pylori is the bacterial adherence to the gastric
mucosa (Bitzan et al., 1998).
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In 1999, Warny et al. revealed that bovine immunoglobulin concentrate, also
known as hyperimmune colostrum, was obtained from cows that were immunized against
Clostridium difficile. This bovine immunoglobulin concentrate (BIC) against C. difficile
resisted digestion in the upper gastrointestinal tract in humans, as well as resisted anti-C.
difficile toxin A binding (Warny et al., 1999). For the study, 5 grams of reconstituted
BIC-C difficile, containing 2.1 g of bovine IgG, was administered orally to volunteers in
250 milliliters (mL) of the marker isosmotic polyethylene solution containing 421 mg of
sodium bicarbonate along with a standard meal (Warny et al., 1999). After the treatment,
the volunteers were required to fast for 4 hours, and then the volunteers were allowed to
consume clear liquids until the end of the six hour ileostomy fluid collection period
(Warny et al., 1999). The volunteers of this particular study were studied on 4 separate
occasions with a 72 hour latent period. Warny et al. (1999) reported 49% of the free
bovine IgG from the ileum after oral administration of BIC-C difficile, indicating that this
residual anti-C difficile BIC may be available in the gut as a useful non-antibiotic
treatment for the prevention and treatment of C. difficile infections.
In 2006, Xu et al. reported a method to produce bovine colostral antibodies
against 17 specific enteric pathogens including 12 E. coli, two Salmonella and three
Shigella. The study revealed that purified IgG isolated from cows immunized with
multivalent vaccine consisting of whole cells of the 17 bacterial strains had a strong
inhibitory effect on in vitro growth and colonization of the pathogens, as well as
preventative effect on enteroinvasive Escherichia coli/Salmonella typhi-infected mice
(Xu et al., 2006). Xu et al. (2006) revealed that these purified hyperimmune bovine
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colostrum IgGs were effective in preventing pathogen growth in vitro by agglutinating
with the bacteria and destroying the bacterial cells walls. However, Xu et al. (2006)
found that IgG obtained from colostrum from non-immunized cows significantly
increased the growth of the pathogens in vitro. To obtain these results, Xu et al. (2006)
transferred 100 µl of each culture of the 12 E. coli, two Salmonella and three Shigella
bacterial species suspension into 5 ml of Bacto Synthetic Broth (BSB), along with the
hyperimmune colostral IgG or the normal colostral IgG. After 12 hours post-treatment,
the bacterial suspensions were examined spectrophotometrically at 570 nanometers (nm);
additionally, the bacterial suspensions were serially diluted and plated onto BSB agar
plates to be incubated at 37ºC for 24 hours and counted for population growth (Xu et al.,
2006). Along with in vitro studies, Xu et al. (2006) performed a mouse study to show the
potential use of the hyperimmune colostral antibodies for treatment of enteric pathogens.
Mice were infected orally once with 0.5 ml of enteroinvasive E. coli and Salmonella typhi
containing 1×108/ml, in addition to being treated with IgG obtained from immunized or
non-immunized cows for 10 days (Xu et al., 2006). On the tenth day, the mice were
sacrificed and the spleen was examined for immunological factors, such as natural killer
cells activity, interleukin-2, and tumor necrosis factor alpha (TNF-α) activity (Xu et al.,
2006).

Xu et al. (2006) reported the hyperimmune IgG prevented enteroinvasive

Escherichia coli/Salmonella typhi-induced diarrhea and enhanced splenic immune
responses by increasing natural killer cell activity, elevating interleukin-2 levels, and
inhibiting the release of TNF-α in mice; thereby, the results indicated the potential
protective effects of bovine colostral antibodies for enteric pathogens (Xu et al., 2006).
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In 2003, Tawfeek et al. examined the use of bovine hyperimmune immuglobulin
concentrate containing antibodies against enteropathogenic E. coli in preventing diarrheal
symptoms in 125 infants in a randomized, double-blind, controlled field trial conducted at
the Al-Sheikh Omer Maternal and Child Health Center in Baghdad, Iraq from May to
September 1998 (Tawfeek et al., 2003). In the study, Tawfeek et al. (2003) found that
infants receiving formula containing hyperimmune bovine colostrum for seven days had
a lower incidence of diarrhea than the infants receiving a non-supplemented formula for
seven days (Tawfeek et al., 2003). Tawfeek et al. (2003) findings suggested that use of
infant formulas supplemented with hyperimmune bovine colostrum could provide an
effective method for preventing enteropathogenic Escherichia coli (EPEC) infections and
diarrheal symptoms.
In 2007, Cesarone et al. examined the effect of orally-consumed, non-immunized
bovine colostrum (400 mg, no commercial brand indicated) in the prevention of influenza
symptoms with and without influenza vaccination. During a three month observation
period, 144 healthy individuals of both sexes ranging in age from 30 to 80 years were
either treated with a bovine colostrum tablets alone, an influenza vaccination alone,
bovine colostrum tablets plus an influenza vaccine, or no treatment. Cesarone et al.
(2007) reported the non-colostrum treated groups had three times longer days of
influenza symptoms than those study participants who had received colostrum
prophylaxis. The researchers suggested the higher number of influenza episodes in the
vaccinated group may have been induced by the vaccination itself in some individuals;
however, the authors did not identify the type of vaccine used in the study (Cesarone et
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al., 2007).

Additionally, Cesarone et al. (2007) indicated that bovine colostrum

prophylaxis may be a cost-effective, safe treatment to prevent influenza symptoms but
additional evaluation studies in high-risk groups were recommended.

Microbial Aspects of Colostrum Products
Lactic acid bacteria (LAB) comprise a group of Gram positive bacteria that are
linked into a single category due to similar morphological, metabolic, and physiological
characteristics. Due to these traits, LAB are generally utilized for a variety of industrial
food and feed fermentations. These bacteria essentially cause the rapid acidification of
food substances through the production of organic acids, mainly lactic acid (Leroy et al.,
2004).

Additionally, the production of acetic acid, ethanol, aroma compounds,

bacteriocins, exopolysaccharides, and several enzymes by LAB improve microbial safety
and contribute to the organoleptic properties of the end product (Leroy et al., 2004).
Research on the genetics, metabolism and application of LAB for functional properties in
foods is an intensifying area of research.
LAB were initially categorized as a group based on the ability to ferment and
coagulate milk (Stiles et al., 1997). Since the early 1900s, the influence of selected
lactobacilli in various food fermentations has been well established. Orla-Jenson in 1919
stated that “the „true lactic acid bacteria‟ form a natural group of Gram-positive,
nonmotile, non-sporeforming, rod- and coccus-shaped organisms that ferment
carbohydrates and higher alcohols to form chiefly lactic acid” (Stiles et al., 1997).
Additionally, in the 20th century, Elie Metchnikoff at the Pasteur Institute in Paris
promoted the use of lactobacilli in the human diet for bacterioprophylaxis and
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bacteriotherapy, but the proposed practice failed to be recognized due to lack of scientific
evidence (Stiles et al., 1997).
Currently, the category of LAB has been further studied and classified according
to similar characteristics.

The most common genera of food-grade LAB include

Lactobacillus, Lactococcus, Pediococcus, Leuconostoc, and Bifidobacterium (Stiles et al.,
1997). Phenotypic characteristics that define the category of LAB include being Grampositive, low G+C (guanine plus cytosine) content, non-sporeforming bacteria that grow
under microaerophilic to strictly anaerobic conditions and are usually catalase-negative
(Stiles et al., 1997). Yet, it must be noted that LAB should not be confused with the
endospore-forming lactic acid-producing bacteria which are aerobic to facultatively
aerobic and are classified in the genera Bacillus and Sporolactobacillus (Stiles et al.,
1997).
The classification of LAB is still fairly controversial since their broad
physiological definition could comprise almost 20 genera of bacteria (Stiles et al., 1997).
Classification of lactic acid bacteria is usually based on morphology, mode of glucose
fermentation, growth at different temperatures, configuration of the lactic acid produced,
ability to grow at high salt concentrations, and acid or alkaline tolerance (Caplice et al.,
1999). Additionally, fatty acid composition and cell wall components are often used for
classification purposes (Caplice et al., 1999).
Ecological niches of LAB can be in the gastrointestinal system of man and animal
and also in fermented food. Due to survival in the gastrointestinal system of man and
animals, LAB are of interest for their function as probiotics. LAB that serve as probiotics
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are able to produce “antimicrobial substances, sugar polymers, sweeteners, aromatic
compounds, useful enzymes, or nutraceuticals” (Leroy et al., 2004). The survival of LAB
and their classification as a probiotic is based on their resistance to low pH and/or bile,
temperature growth ranges, carbohydrate fermentation patterns, resistance to different
NaCl concentrations, and resistance against antibiotics.
The 16 S RNA sequencing has improved identification for LAB. Sequencing of
the 16 S rRNA has divided lactic acid bacteria into three phylogenetic groups:
1. The group Lactobacillus delbrueckii contains this species and other strictly
homofermentative lactobacilli;
2. The group Leuconostoc is divided into two subgroups: one containing Lc.
paramesenteroides and heterofermentative lactobacilli; the other containing
Leuconostoc sensu stricto, to which Oenococcus oeni belongs;
3. The group Lactobacillus casei - Pediococcus is a more heterogeneous group
since it comprises strictly and facultatively heterofermentative species and
strictly homofermentative species (Rib´ereau-Gayon et al., 2006).
Grouping by means of 16 S rRNA sequences is based on phylogenetic relationships
between bacteria. Analyzing and classifying the conserved 16 S rRNA of LAB does not
always follow the grouping pattern revealed by using phenotypes, such as morphology
and physiology. Therefore, physiological and biochemical criteria remain useful, but the
findings and relationships discovered by molecular taxonomy are significant and are
more conclusive since this reveals the genetic evolution of LAB (Rib´ereau-Gayon et al.,
2006).
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The two main sugar fermentation pathways can be distinguished within the
classification of lactic acid bacteria: homolactic fermentation (homofermentative) and
heterolactic fermentation (heterofermentative).

Homofermentative bacteria such as

Pediococcus, Streptococcus, Lactococcus, and some lactobacilli produce lactic acid as
the sole end product of glucose fermentation (Rib´ereau-Gayon et al., 2006). Under
altered growth conditions when pentose is the initial substrate, homofermentative bacteria
use the Embden- Meyerhof- Parnas or Glycolysis Pathway to generate two moles of
lactate per mole of glucose and derive twice as much energy per mole of energy as
heterofermentative bacteria (Caplice et al., 1999). Heterofermentative bacteria such as
Weisella and Leuconostoc (Rib´ereau-Gayon et al., 2006), and some lactobacilli produce
equimolar amounts of lactate, carbon dioxide, and ethanol from glucose via the hexose
monophosphate or pentose pathway (Caplice et al., 1999).

The metabolism of the

dissacharide lactose is of primary importance for LAB used in dairy fermentations
(Caplice et al., 1999). Lactose may enter the cell by a lactose carrier such as lactose
permease.

Then, the sugar lactose is cleaved into glucose and galactose via a

phophoenolpyruvate-dependent phosphotransferase (PTS).

Next, the glucose and

galactose are cleaved into glucose and galactose-6-phosphate via the tagatose-6phosphate pathway (Caplice et al., 1999). The lactic acid produced may be L(+) or , less
frequently, D(-), or a mixture of both. It should be noted that D (-) lactic acid is not
metabolized by humans (Caplice et al., 1999).

End products of these fermentation

processes can be altered by stress conditions. These alterations can be attributed to an
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altered pyruvate metabolism or the use of external electron acceptors such as oxygen.
(Salminen et al., 2004).
Essentially, LAB fermentation pathways are started by creating a proton motive
force by utilizing H+-ATPases located in the cell membrane at the expense of ATP to
transport metabolites and ions into the bacterial cell. Extrusion of end-products and
transport of certain compounds outside of the bacterial cell may contribute to the protonmotive force, thus not utilizing ATP. Proton motive force-dependent permease systems
or phosphoenolpyruvate: sugar phosphotransferase systems primarily modulate sugar
transport.

Therefore, sugar transport is a coordinated pathway to efficiently bring

hexoses and pentoses into the bacterial cell (Salminen et al., 2004).
In addition to carbohydrate fermentation, citrate metabolism is important among
L. lactis subsp. lactis (biovar diacetylatic) and Lc. mesenteriodes subsp. cremoris strains
used in the dairy industry, as it results in excess pyruvate in the cell. The pyruvate may
be converted via alpha-acetolactone to diacetyl, an important flavor and aroma
component of butter and some other fermented dairy products.

Moreover, carbon

dioxide can be produced due to citrate metabolism, and this gas production can contribute
to the formation of "eyes" or holes in Gouda, Danbo and other cheeses (Quintans et al.,
2008).
Also, the proteolytic system of lactococcus has been recently examined due to its
pivotal role in allowing growth in milk and the development of flavor and texture in
cheese (Quintans et al., 2008). With the proteolytic system, casein is degraded by serine
proteinase (PrtP) located in the bacterial membrane. The degradation of casein results in
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small oligopeptides being transported into the cells via an oligopeptide transport system
(Opp), where they are further processed by a variety of intracellular peptidases. Most
commercial starter cultures promote proteolysis in cheese and can aid in the development
of a consistent cheese flavor (Quintans et al., 2008).
In early 1900s, the interactions of LAB in foods received attention of scientists
and resulted in the significant contribution by Pasteur on lactic acid fermentation in 1857,
followed by the first isolation of a pure bacterial culture, Bacterium luctis, by Lister in
1873 (Stiles et al., 1997).

In 1890, Weigrnann in Kiel, Germany and Starch in

Copenhagen, Denmark began using starter cultures for cheese and sour milk production
(Stiles et al., 1997).

This finding opened the door for industrialization of food

fermentations utilizing bacteria. However, the association of LAB with food-making
dates back several thousand years. Archeological excavations in Switzerland indicated
that sourdough bread was made over 5000 years ago.

Biblical references mention

leavened breads, and ancient texts from around 3200B.C. describe fermented dairy
products such as cheese, yogurt and butter in use in the area of modern-day Iraq (Stiles et
al., 1997). Additionally, Babylonians utilized fermentation to brew beer which was
exported to Egypt around 3000 B.C. (Stiles et al., 1997).
Although LAB are usually involved in a large number of food fermentations, they
also are closely associated with the human environment. Recently, claims that LAB are
important in human and animal health are receiving renewed attention as health
promoting, probiotic agents, and especially strains which are purported to have a
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stabilizing or favorable influence on the gastrointestinal tract due to the ability of LAB to
survive the gastrointestinal tract (Stiles et al., 1997).
The production of inhibitory substances, like bacteriocins, by LAB is an area of
increasing interest by researchers and industry members. Strains, such as Lc. Luctis,
produce a wide range of bacteriocins such as the antibiotic nisin. Nisin is a broad
spectrum bacteriocin that is active against Gram positive bacteria, including Clostridium
botulinum and its spores (Stiles et al., 1997).
The lactobacilli are strictly fermentative and have complex nutritional
requirements. They are able to inhabit various habitats. Lactobacilli are aciduric or
acidophilic.

Lactobacillus acidophilus is considered an important representative of

probiotic bacteria. In 1982, Kleeman and Klaenhammer studied the bacterial strain Lb.
acidophilus BG2 F04 and re-identified the strain as Lb. johnsonii (Stiles et al., 1997).
This strain adheres to human intestinal cells in vitro (Stiles et al., 1997). Currently, Lb.
johnsonii is utilized in yogurts and supports the claims on healthfulness due to population
competition (Stiles et al., 1997). This species and other Lb. acidophilus strains are
currently being studied for their probiotic properties such as microbial antagonism,
survival through the stomach passage, growth and metabolic behavior in the small and
large intestine, and attachment to the epithelial cells of the gut (Stiles et al., 1997).
Previous studies have indicated beneficial health consequences due to LAB and their
cellular products. In the study of colostrum, it is unknown if LAB influence health
consequences of consuming the nutraceutical or vice versa.

25

In addition to the lactic acid bacteria, members of the Bacillus, Pseudomonas,
Kocuria, Microbacterium, and Enterococcus genera can be present in dried dairy dietary
supplements. Bacillus licheniformis is a common industrial, environmental, and dairy
contaminant. B. licheniformis is closely related to B. subtilis, and has been associated
with a range of conditions such as septicemia, peritonitis, ophthalmitis, and food
poisoning in humans, as well as with bovine toxemia, mastitis, and abortions (SalkinojaSalonen et al., 1999; Blue et al., 1995; Blowey and Edmondson, 2010). Conditions and
food poisoning cases caused by B. licheniformis are typically caused by bacterial levels
of 105 to 109 cfu/g (Lund et al., 2000). However, the toxigenic Bacillus cereus is
responsible for more food poisoning incidents than Bacillus licheniformis. However, the
involvement of toxins produced by B. licheniformis has not yet been demonstrated
(Salkinoja-Salonen et al., 1999).

Although B. licheniformis can be classified as

pathogenic, this bacterium is often modified for enzyme production to digest bird feathers
or laundry detergent proteases among other commercial applications (Salkinoja-Salonen
et al., 1999; de Boer et al., 1994).
Bacillus subtilis is a bacterium commonly found in the environment.

This

bacterium is not often associated with food-borne illness. However, if food does become
contaminated, B. subtilis spores can survive the extreme heat during cooking.
Additionally, B. subtilis can uptake external environmental DNA by recombination and
activate sigma factor B, which allows the bacteria to adapt to stressful and harsh
conditions (Bandow et al., 2002).
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In comparison to the well-understood B. subtilis and B. licheniformis, Bacillus
massiliensis was isolated in 2004 from human cerebrospinal fluid. Based on comparative
analysis of 16S rRNA gene sequences and phenotypic characteristics, the novel isolate
has only been described as being related to the Bacillus sphaericus-like group. The
isolate is closely related to Bacillus odysseyi and Bacillus silvestris (Glazunova, et al.,
2006).
Bacillus pumilus is the predominant species of the environmentally common
Bacillus species. This bacterial species is highly resistant to extreme environmental
conditions such as low or no nutrient availability, desiccation, irradiation, peroxide and
other chemical disinfections. B. pumilus is of interest commercially since this bacterial
species produces anti-fungal and anti-bacterial compounds (Gioia et al., 2007; Parvathi et
al., 2009).
Bacillus badius have been isolated from many environmental and food sources
such as feces, dust, marine sources, and antacids (Saghafi and Appleman, 1952; Jutur and
Reddy, 2006).

Particularly, B. badius has been isolated from the intestinal tract of

children administered a diet of milk (Batchelor, 1918).

B. badius colonies

characteristically form unique rhizoid outgrowths (Saghafi and Appleman, 1952; Jutur
and Reddy, 2006).
Pseudomonas fluorescens is the most common psychotrophic bacteria isolated
from the dairy environment. P. fluorescens produces heat-stable lipases, proteases, and
lecithinases that survive thermal processing techniques (Sillankorva et al., 2008).
Commonly, this bacterium can easily form biofilms, thereby, P. fluroescens is used as a
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model organism for biofilm studies. Listeria monocytogenes increase colonization on
inert surfaces due to the presence of P. fluorescens (Carpentier and Chassaing, 2004).
Additionally, Carpentier and Chassaing ( 2004) reported P. fluorescens biofilms protect
pathogenic bacteria from disinfection processes.
Kocuria rhizophila, formerly known as Micrococcus luteus, (Tang and Gillevet,
2003), is a common contaminant of dairy products, which can facilitate its transmission
to a host after consumption of milk (Lillo et al., 1997). Lillo et al., 1997 demonstrated the
susceptibily of microbes to lactorferrin utilizing K. rhizophila. Enterococcus faecium is
an inhabitant of the mammalian gastrointestinal tract. It is a common probiotic
component, yet it is highly resistant to multiple antibiotics (Solheim et al., 2009).
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MATERIALS AND METHODS

Colostrum Samples
Four brands of dried colostrum and two brands of dried whey were obtained on
three different days from the same nutraceutical company over a three month period.
One brand of non-fat dry milk was purchased from a local grocery store on three different
days over a three month period. Each sample was submitted in duplicate to the Clemson
University Agricultural Services Laboratory for analysis of fat, protein, and ash/mineral
content analyses.

IgG Concentration- Immunoprecipitation Assay
Concentration of IgG was determined by immunoprecipitation using a VMRD
Single Radial Immunodiffusion kit (VMRD, Inc., 240-60, Pullman,WA). Each dairy
product (1g into 9 ml) was rehydrated in Class O phosphate and magnesium chloride
buffer (Wehr and Frank, 2004) for total IgG determination. Colostrum Brand A was also
rehydrated in phosphate and magnesium chloride buffer, along with 1% n-octyl-β-Dglucopyranoside (Sigma-Aldrich Co., O8001, St. Louis, MO) to solubilize membrane
bound immunoglobulins due to inability of Colostrum Brand A to go into solution. All
samples were brought to room temperature and samples were mixed thoroughly for 1
hour on a shaker before use. Three microliters of each sample and reference standard
was applied to serial radial immunodiffusion plates containing agarose gel with antibovine IgG. After sample addition, plates were incubated undisturbed for 24 h at room
temperature.

Samples positive for IgG exhibited opaque rings around the sample.
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Resulting ring diameters were measured, and IgG content of samples was calculated by
regression analysis. A standard curve was generated with reference sera supplied by the
manufacturer.

Bacterial Enumeration
Initial microbiological examination of colostrum products involved standard dairy
product enumeration techniques. Whey and non-fat dried milk were not included in the
initial bacterial enumeration experiments.

Standard plate count agar (SPC) (VWR,

90000-250, West Chester PA), violet red bile agar (VRBA) (VWR, 90000-280,West
Chester PA), and Elliker's agar (VWR, 95021-728, 90000-764, West Chester PA) were
used and incubated at 32 ± 2°C for 72 h, 32 ± 2°C for 24 h and 32 ± 2°C for 48 h,
respectively (Wehr and Frank, 2004). Class O phosphate/magnesium chloride buffer was
used as the diluent (Wehr and Frank, 2004) and a lecithin-based buffer were used as the
diluents. The lecithin-based buffer contained 10% ADM Ultralec® F Deoiled Lecithin
added to standard phosphate/magnesium chloride buffer. For dried dairy products, diluent
bottles were pre-warmed to 40 to 45°C. Samples were aseptically weighed into the
tempered diluent and mixed by shaking in a 1 foot arc for 20 to 30 revolutions (Wehr and
Frank, 2004). Samples were plated using the pour plate method at 100 to 10-6 dilutions.
For the 100 dilution, 1 gram of sample was weighed aseptically directly into the sterile
Petri dish.
Samples of colostrum, whey, and non-fat dry milk were examined in duplicate for
identifying the bacterial species in the products using both Elliker‟s agar (VWR, 95021728, 90000-764 West Chester PA) and Standard Plate Count agar (SPC) (VWR, 90000-
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250, West Chester PA). One gram of each product was weighed directly into Petri dishes
and then adding tempered agar. Plates were incubated for approximately 48 h at 35°C.
Individual colonies were selected from plates and then streaked for isolation on Elliker‟s
agar or SPC agar. The Gram reactions and colony morphologies were recorded.

Bacterial Identification via Colony PCR and 16S rRNA
Individual colonies were selected from plates. A small amount of an isolated
bacterial colony was added with a sterile inoculating loop to a sterile PCR reaction tube
along with 50 µl of Promega nuclease-free water (VWR, PAP1195, West Chester PA).
Tube was placed into boiling water for 10 min. A 12.5 µl sample of the boiled mixture to
be used as a DNA template was added to a sterile PCR reaction tube. One µl of forward
oligonucleotide primer (8F, 5'AGAGTTTGATCMTGGCTCAG 3', Integrated DNA
Technologies, Coralville, IA), 1 µl of reverse oligonucleotide primer (1492R,
5'GGYTACCTTGTTACGACTT 3‟, Integrated DNA Technologies, Coralville, IA), 10
µl of GoTaq® Green Master Mix (VWR, PAM7122, West Chester PA) were added to the
PCR reaction tube.
The thermal cycle program consisted of one cycle of 94°C for 30 s, 50.6°C for 30
s, 72°C for 1 min, repeat for 30 cycles, and a final incubation at 4°C. The PCR-amplified
fragments were observed by gel electrophoresis in 1.5% agarose gels. Ten µl of each
PCR product and the HyLadder™ molecular mass marker (Denville Scientific Inc.,
CB4225-2, Metuchen, NJ) was examined using agarose gel electrophoresis with
subsequent Sybr™ Safe DNA gel (S33102, Invitrogen, Carlsbad, California) staining.
The amplified DNA fragments were visualized by UV illumination. The PCR
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purification was accomplished using a Promega PCR Clean Up kit (VWR, PAA9281,
West Chester PA). The 16S rRNA sequencing was completed by the Clemson University
Genomic Institute. Sequences were analyzed with National Center for Biotechnology
Information (NCBI) BLAST database (Altschul et al., 1997).

Antimicrobial Disk and Well Diffusion Assays
Antimicrobial activity of each dairy product was determined using disk diffusion
and agar-well diffusion assays. For the disk diffusion assays, each dairy product was
diluted (1 g in 9 ml) using phosphate and magnesium chloride dilution water (Class O)
(Wehr and Frank, 2004) and allowed to rehydrate for approximately 5 min. Autoclaved,
sterile, cotton paper disks were suspended into the rehydrated dairy products and were
aseptically placed onto Petri plates containing SPC agar (VWR, 90000-250, West Chester
PA). The plates were incubated at 35°C and were examined for zones of inhibition at 24
h and 48 h of incubation.
For the agar-well diffusion assays, each dairy product was diluted (1 g in 9 ml)
using phosphate and magnesium chloride dilution water (Class O) (Wehr and Frank,
2004). Approximately 50 µl of each rehydrated dairy products were aseptically placed
into approximately 5 mm wells in Petri plates containing 0.7% TSA agar (VWR, 90002700, West Chester PA) (Benkerroum et al., 2000) or BHI Agar (VWR, 90003-262, West
Chester PA) (Nowroozi et al., 2004). Both methods were examined with the Grampositive Staphylococcus aureus (ATCC 25922) and Gram-negative E. coli (ATCC
25909). The 0.7% TSA plates were incubated at 35°C and were examined for zones of
inhibition at 24 h and 48 h of incubation. The BHI plates were incubated at 4°C for 24 h
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and then the plates were incubated at 35°C for 24 h. The BHI plates were examined for
zones of inhibition at 24 h and 48 h of 35°C incubation.
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RESULTS AND DISCUSSION

Colostrum Samples
Samples were labeled Colostrum Brand A, Colostrum Brand B, Colostrum Brand
C, Colostrum Brand D, Whey Brand A, Whey Brand B, and Non-Fat Dry Milk Brand A.
Colostrum Brand A was loose powder whereas Colostrum Brands B, C and D were
powder in gelatin capsules. Whey Brands A and B and Non-Fat Dry Milk Brand A were
loose powder. Label claims including immunoglobulin content (percent composition of
weight), fat-free claims, and daily dosage recommendations from each sample are
recorded from each sampled dried dairy dietary supplement in Table 2 (Symbiotics©,
2010;

The

Vitamin

Shoppe©,

2010;

Nutraceutical

Corporation©,

2010;

FoodScienceCorp©, 2010; DESIGNER WHEY®, 2010; Country Life, LLC, 2010;
Ingles Markets Inc©, 2010).

Table 2. Label Claims Presented on Sampled Dried Dairy Dietary Supplements.
Dried Dairy
Product
Colostrum
Brand A
Colostrum
Brand B
Colostrum
Brand C
Colostrum
Brand D
Whey
Brand A
Whey
Brand B
Non-Fat Dried
Milk
Brand A

Immunoglobulins
Percent
Immunoglobulin per Daily Dosage

Fat-Free
Claim

Recommended Daily
Dosage (mg)

25

240

No

32

40

190

No

475

30

200

No

2500

30

180

Yes

30

No claim

N/A

Yes

23247

No claim

N/A

No

85049

No claim

N/A

No

No recommendation
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Chemical analyses of the individual dried dairy dietary supplements indicated
product variations between and within brands. Results are presented in Table 3.

Table 3. Mean Chemical Composition ± Standard Deviation of Duplicate Sampled Dried
Dairy Dietary Supplements.
Dried Dairy
Product

Protein ±
Std Dev
(%)

Fat
± Std Dev
(%)

Ash
± Std Dev
(%)

Moisture
± Std Dev
(%)

Dry Matter
± Std Dev
(%)

Colostrum
Brand A

48.8±4.0

20.4±11.6

6.6±1.8

8.7±1.1

91.4±1.1

Colostrum
Brand B

75.8±4.1

0.1±0.0

6.2±0.2

9.7±1.9

90.3±1.9

Colostrum
Brand C

77.5±4.2

0.1±0.0

6.2±0.1

11.8±2.6

88.2±2.6

Colostrum
Brand D*

43.8±0.7

19.1±1.8

16.7±0.2

11.5±0.6

88.3±0.4

Whey
Brand A*

91.4±2.9

0.6±0.7

2.9±0.0

8.0±3.8

92.0±3.8

80.9±4.5

0.5±0.6

4.9±0.0

8.6±2.5

91.5±2.5

35.6±0.9

0.5±0.2

7.8±0.0

3.5±0.2

96.6±0.2

Whey
Brand B
Non-Fat
Dried
Milk
Brand A

(*) indicates the product does not adhere to non-fat label claims.

The legal definition for fat-free dairy products is 0.5% or less fat. Results indicate
that Colostrum Brand D did not adhere to label claims regarding fat content and instead
of being "fat-free" as listed on the label, the product contained greater than 19% fat.
Whey Brand A contained slightly greater than 0.5% fat although label claims indicated
the product was fat-free. The Dietary Supplement Health Education Act of 1994 directs
that dietary supplement labels must be truthful and not misleading (Food and Drug
Administration, 2010). However, the FDA Food Safety Modernization Act, a bill passed
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by the US House of Representatives and introduced into the US Senate March 3, 2009 is
still under debate. This bill has the potential to expand the power of the FDA, specifically
the Secretary of Health and Human Services (HHS), to regulate all foods sold,
distributed, or imported within the US, including dietary supplements (Civic Impulse,
LLC, 2010). Results of this study indicated significant errors in label claims on one
colostrum and one whey product. In addition, the fat content of Colostrum Brand A was
determined to be 20.4±11.6% probably due to the biolipid delivery system advertised by
the manufacturer. The high standard deviation indicated considerable variability between
duplicate samples.

Total IgG Concentration- Immunoprecipitation Assay
The total IgG concentration of colostrum, whey and non-fat dry milk products
involved quantification via single radial immunodiffusion kits (VMRD, Inc., 240-60,
Pullman, WA). Single radial immunodiffusion is a commonly used time and temperature
dependent method for classification and quantification of immunoglobulins (VMRD, Inc,
2010). Specific anti-bovine IgG are incorporated into the commercially made agarose gel
plates. When each rehydrated dairy dietary supplement sample is added into wells of the
agarose plates, the bovine IgG antigen diffuses into the agarose gel containing the
antibody forming a precipitant ring that is proportional to the concentration of the IgG
concentration in each product (VMRD, Inc, 2010). Total IgG concentration of the
individual dried dairy dietary supplements indicated variations from label claims (Table
2). Results are presented in Table 4.
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Table 4. Total IgG Concentration of Sampled Dried Dairy Dietary Supplements.
Dried Dairy
Total IgG
Total IgG
Average IgG
Average
Product
Concentration
Concentration Concentration
Variation
(mg)
(mg)
± Std Error
from Label
(mg)
Claim (%)
Sample Lot # 1
Sample Lot # 2
32
>4
18±9.9
13.3
Colostrum
Brand A
24
>4
14±7.1
12.6
Colostrum
Brand A*
32
24
28±2.9
14.7
Colostrum
Brand B
5.2
5.2
5.2±0
2.6
Colostrum
Brand C
27
8
17.5±6.7
9.7
Colostrum
Brand D
4
>4
4±0
No label
Whey Brand
claims
A
4
5.2
4.6±0.45
No label
Whey Brand
claims
B
0
0
0±0
No label
Non-Fat
claims
Dried Milk
Brand A
(*) indicates the addition of 1% n-octyl-β-D-glucopyranoside (Sigma-Aldrich Co.,
O8001, St. Louis, MO)

Results indicate that Colostrum Brands A, B, C, and D contained from 2.6 to
13.3% lower mean immunoglobulin content than label claims. Therefore, the products
did not adhere to label claims regarding immunoglobulins and, thereby, did not adhere to
the Dietary Supplement Health Education Act of 1994 (Food and Drug Administration,
2010). Chelack et al. (1993) reported that spray dried bovine colostrum conducted at a
low temperature can cause loss of immunoglobulin function and quantity. Results of this
study indicated significant errors in label claims on all colostrum products.
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Bacterial Enumeration
Initial microbiological examination of colostrum, whey and non-fat dry milk
products involved standard dairy product enumeration techniques on two lots of dried
dairy dietary supplements, not including the whey and non-fat dried milk. However,
difficulties in identifying colonies versus dairy product particles were noted (Tables 5
through 18). Various techniques were attempted to resolve difficulties in enumeration.
Aseptically grinding of samples, blending, longer rehydration periods, lecithin-based
buffers and different dilution rates were attempted but all methods were unsuccessful.
Results demonstrate the inconsistencies in the plate counts obtained from serially diluted
dried dairy products according to the standard dairy product enumeration techniques on
standard plate count agar (VWR, 90000-250, West Chester PA), violet red bile agar
(VWR, 90000-280,West Chester PA), and Elliker‟s agar (VWR, 95021-728, 90000-764,
West Chester PA). The plate counts and bacterial growth on all media (Tables 5 through
18) did not always reduce according to the dilution factor. Dried dairy products are white
powdered materials that often are difficult to differentiate from the white bacterial
colonies formed on the plates. Additionally, the high fat content of the dried dairy
products (Table 2) may have encapsulated the bacteria within the dried dairy dietary
supplements causing the bacteria to not be enumerated properly. Dried dairy dietary
supplements have high protein concentrations (Table 2) that could lead to bacterial
attachment to the polystyrene Petri dishes (Fletcher, 1975); thereby, impairing
enumeration of bacterial content of the dried dairy dietary supplements. In future studies,
silicon treated glass or polylysine Petri dishes may be tested.
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In Table 5, the results of the SPC enumeration of Colostrum Brand A indicated
Lots 1 and 2 were different. However, since dilutions of 2 replicates in Lot 1 did not
indicate proper 1 to 10 reductions and were thought to be in error. Statistical analysis was
not conducted. In Table 6, the results SPC results for Colostrum Brand B indicated the
two lots were different. However, serial dilutions were obviously in error since counts did
not abide by 1 to 10 reductions in numbers. Therefore, since enumeration errors were
noted, statistical analysis was not conducted. In the SPC results for Colostrum Brand C
(Table 7), Lots 1 and 2 were different. No bacterial colonies were noted on Lot 1, but on
Lot 2 counts did not match serial dilutions indicating an error. Since enumeration errors
were noted, statistical analysis was not conducted. The SPC results for Colostrum Brand
D (Table 8), Lot 1 indicated erratic counts that did not correspond to the dilution. For Lot
2, plates were lost due to a laboratory accident after incubation and after disposal of
original samples. Therefore, comparisons between Lots 1 and 2 could not be made or
statistically analyzed. However, since all other enumeration results were obviously in
error, repeating the experiment was not deemed useful.
Coliform counts from Colostrum Brands A-D are listed in Tables 9-12,
respectively. Coliform counts are used by the dairy industry as an indication of proper
hygiene and sanitation. According to the US Pasteurized Milk Ordinance (2007), the
legal limit for coliform in dried dairy products in 10 CFU/g. In Tables 9, 10, 11, and 12,
all

Colostrum

Brands

and

Lots,

except

in violation on coliform count.
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Brand

C,

Lot

1

were

Table 5. Standard Plate Count of Sampled Dried Dairy Dietary Supplement Colostrum
Brand A.
Colostrum Brand
A
Dilutions

10-1
10-2
10-3
-4

10
10-5
10-6

Standand Plate Count
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
TNTC
TNTC
0
2
178
162
0
0
40
8
0
0

51
2
2
0

0
0
0
0

0
0
0
0

Table 6. Standard Plate Count of Sampled Dried Dairy Dietary Supplement Colostrum
Brand B.
Colostrum Brand
B
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Standand Plate Count
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1 Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
220
148
5
6
42
38
2
0
210
110
1
0
0
3
0
0
0
1
0
0
0
0
0
0
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Table 7. Standard Plate Count of Sampled Dried Dairy Dietary Supplement Colostrum
Brand C.
Colostrum Brand
C
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Standand Plate Count
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
0
0
17
40
0
0
42
2
0
0
2
6
0
0
25
1
0
0
0
0
0
0
0
0

Table 8. Standard Plate Count of Sampled Dried Dairy Dietary Supplement Colostrum
Brand D.
Colostrum Brand
D
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Standand Plate Count
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
Experimental Experimental
9
19
Error
Error
Experimental Experimental
101
9
Error
Error
Experimental Experimental
1
1
Error
Error
Experimental Experimental
0
0
Error
Error
Experimental Experimental
0
0
Error
Error
Experimental Experimental
0
0
Error
Error
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Table 9. Violet Red Bile Agar Coliform Count of Sampled Dried Dairy Dietary
Supplement Colostrum Brand A.
Colostrum Brand
A
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Violet Red Bile Agar Coliform Count
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
1
2
1
4
1
4
0
0
1
3
0
0
4
3
0
0
9
1
0
0
1
0
0
0

Table 10. Violet Red Bile Agar Coliform Count of Sampled Dried Dairy Dietary
Supplement Colostrum Brand B.
Colostrum Brand
B
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Violet Red Bile Agar Colony Forming Units
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
TNTC
TNTC
TNTC
TNTC
85
72
TNTC
TNTC
8
2
44
100
0
0
51
27
0
0
0
0
0
0
0
0
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Table 11. Violet Red Bile Agar Coliform Count of Sampled Dried Dairy Dietary
Supplement Colostrum Brand C.
Colostrum Brand
C
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Violet Red Bile Agar Colony Forming Units
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
0
0
10
83
0
0
105
3
0
0
8
15
0
0
6
10
0
0
0
0
0
0
0
0

Table 12. Violet Red Bile Agar Coliform Count of Sampled Dried Dairy Dietary
Supplement Colostrum Brand D.
Colostrum Brand
D
Dilutions

Violet Red Bile Agar Colony Forming Units
Sample Lot #1
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)

10-1

16

10

10-2

7

9

10-3

12

6

10-4

12

8

10-5

0

0

10-6

0

0
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Sample Lot #2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
Experimental Experimental
Error
Error
Experimental Experimental
Error
Error
Experimental Experimental
Error
Error
Experimental Experimental
Error
Error
Experimental Experimental
Error
Error
Experimental Experimental
Error
Error

Coliform counts on Colostrum Brand B (Table 10) were too numerous to count
(TNTC), indicating gross contamination. However, results indicated that counts did not
match with serial dilutions. In addition in comparing coliform counts to SPC counts for
the same Colostrum Brand B, it would be expected that coliform counts would be less
since it is a subset of the total plate count. This indicates further error in the enumeration
of colostrum and points out the obvious errors on the SPC and/or coliform counts.
Therefore, statistical analysis was not performed.
It was hypothesized that lactic acid bacteria may be present in colostrum samples.
Growth on Elliker‟s agar was scored as yes or no across 10-1 to 10-6 dilutions of each
colostrum brand (Tables 13-16). Growth was noted on 5 out of 8 lots.
In an effort to improve dispersion of the colostrum products, a lecithin-based
buffer was tested (data not shown). Across all brands, bacterial colony counts were lower
on the lecithin buffer. This effect could be due to lecithin inhibiting or killing inherent
bacteria. Using the standard phosphate/magnesium chloride buffer (Wehr and Frank,
2004), it was difficult to distinguish between clumps of colostrum powder and colonies.
Therefore, lower count on the lecithin could have been due to dispersion of colostrum
and the counted “colonies” could have been true colonies. However, lecithin would act to
disperse fat, it would be expected that this difference in counts would be noted on the
high fat products, Colostrum Brands A and D. No such trend was noted.
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Table 13. Elliker‟s Agar Bacterial Growth of Sampled Dried Dairy Dietary Supplement
Colostrum Brand A.
Colostrum Brand
A
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Elliker’s Agar Bacterial Growth
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
+
+
+
+
+
+
-

Table 14. Elliker‟s Agar Bacterial Growth of Sampled Dried Dairy Dietary Supplement
Colostrum Brand B.
Colostrum Brand
B
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Elliker’s Agar Bacterial Growth
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1 Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
+
+
+
+
+
+
+
+
-

+
-
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+
-

-

Table 15. Elliker‟s Agar Bacterial Growth of Sampled Dried Dairy Dietary Supplement
Colostrum Brand C.
Colostrum Brand
C
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Elliker’s Agar Bacterial Growth
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
+
+
+
+
-

-

+
+
+
+

+
+
+
+

Table 16. Elliker‟s Agar Bacterial Growth of Sampled Dried Dairy Dietary Supplement
Colostrum Brand D.
Colostrum Brand
D
Dilutions

10-1
10-2
10-3
10-4
10-5
10-6

Elliker’s Agar Bacterial Growth
Sample Lot #1
Sample Lot #2
Replicate 1
Replicate 2
Replicate 1
Replicate 2
(CFU/g)
(CFU/g)
(CFU/g)
(CFU/g)
+
+
+
+
+
+
-

Late in the study, a reference was located for utilizing 0.5% tetrazolium chloride
(TTC) added to the agar in an attempt to stain live colonies to a reddish pink color. Using
the hypothesis that TTC would allow differentiation between colostrum powder clumps
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and colonies, it was expected that TTC would improve accuracy of the plate counts.
However, preliminary experiments (results not shown) did not support this hypothesis.
Bacteriological enumeration results indicated that counts across serial dilutions were
inaccurate. For many of the results, greater counts were reported for higher dilutions.
Clearly, further work is needed on improving bacterial enumeration techniques for these
dried dairy supplements. A method is needed to separate the clumps so that bacterial
cells can be accurately dispersed and subsequent colonies on agar can be distinguished
from clumps of the dried dairy powder.

Bacterial Identification via Colony PCR and 16S rRNA
Bacterial isolates from the dried dairy supplement products were selected from
standard plate count agar and Elliker's agar. Isolates were subjected to 16S rRNA
sequencing analysis to amplify the 16S rRNA gene using the forward oligonucleotide
primer (8F, 5' AGAGTTTGATCMTGGCTCAG 3') and the reverse oligonucleotide
primer (1492R, 5' GGYTACCTTGTTACGACTT 3').

Results were submitted for

sequencing to the Clemson University Genomics Institute©.

Data were analyzed using

the BLASTn program on the National Center for Bioinformatics (NCBI) website (Altchul
et al., 1997). Bacterial identity was selected from the top twenty five BLAST nucleotide
database results with max identity greater than 90%. Gram reaction and morphological
characteristics were utilized to confirm the identity of bacterial isolates. Approximately
69% of all bacterial isolates were members the Bacillus genus, while approximately 14%
of all bacterial isolates were identified as members of the Pseudomonas genus (Table 19).
Additionally, members of the Kocuria, Microbacterium, and Enterococcus genera were
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identified as well. Bacillus licheniformis and Pseudomonas fluorescens are common
milkborne organisms. B. licheniformis is a sporeformer and consequently has high heat
resistance.

B. licheniformis has been implicated in mastitis in cows (Blowey and

Edmondson, 2010) and human catheter implants (Blue et al., 1995).

However, B.

licheniformis also has a number of commercial uses due to the variety of proteases,
lipases and carbohydrases the organism produces (de Boer et al., 1994). The Gram
negative Pseudomonas fluorescens is a common milkborne spoilage organism.

It

produces heat resistant enzymes and especially proteases. It can cause bitter flavor
development due to proteolytic release of peptides and has been associated with
formation of ropiness in milk (Michalac et al., 2003).
Although coliform bacteria were enumerated on VRBA, no coliform bacteria
were identified using 16S rRNA analysis. Colonies were selected from SPC and Elliker's
agar. However, coliform bacterial should have been part of the flora on the SPC plates.
No lactic acid bacteria were identified using 16S rRNA sequencing analysis.
Isolates were selected from both standard plate count agar and Elliker's agar. Elliker's
agar isolates should have been members of the lactic acid bacterial group. However,
since universal primers were used, it is hypothesized that the primers did not properly
anneal to the bacterial DNA template during the PCR reaction thereby preventing
identification. Of the 50 isolates derived from the dried dairy supplements and submitted
for sequencing analysis, only 29 were identified.
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Table 19. Bacterial Species Identified from Each Dried Dairy Dietary Supplements Using
16S rRNA Sequencing Analysis.
Dried Dairy Product
and Bacterial Isolate Classification
Colostrum Brand A

Colostrum Brand B

Colostrum Brand C

Colostrum Brand D

Whey Brand A

Gram Reaction
& Cell Morphology

16S Bacteria Identification
(>90% Top Identity
Match)

Isolate 1

Positive Rod

Bacillus licheniformis

Isolate 2

Positive Rod

Bacillus badius

Isolate 3

Positive Cocci

Kocuria rhizophila

Isolate 4

Positive Rod

Bacillus cereus

Isolate 5

Positive Rod

Bacillus badius

Isolate 6

Positive Rod

Bacillus subtilis

Isolate 7

Positive Rod

Bacillus cereus

Isolate 1

Positive Rod

Bacillus licheniformis

Isolate 2

Negative Rod

Pseudomonas fluorescens

Isolate 3

Positive Rod

Bacillus licheniformis

Isolate 4

Positive Cocci

Enterococcus faecium

Isolate 5

Positive Rod

Bacillus massiliensis

Isolate 1

Negative Rod

Pseudomonas fluorescens

Isolate 2

Negative Rod

Pseudomonas spp.

Isolate 1

Positive Rod

Bacillus subtilis

Isolate 2

Positive Rod

Bacillus licheniformis

Isolate 3

Positive Rod

Bacillus subtilis

Isolate 4

Positive Rod

Bacillus subtilis

Isolate 5

Positive Rod

Bacillus licheniformis

Isolate 6

Positive Rod

Bacillus pumilus

Isolate 7

Positive Rod

Bacillus subtilis

Isolate 8

Positive Rod

Bacillus subtilis

Isolate 9

Positive Rod

Bacillus subtilis

Isolate 1

Negative Rod

Pseudomonas fluorescens
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Table 19 (continued). Bacterial Species Identified from Each Dried Dairy Dietary
Supplements Using 16S rRNA Sequencing Analysis.
Whey Brand B

Non-Fat Dried Milk
Brand A

Isolate 1

Positive Rod

Microbacterium
hydrocarbonoxydans

Isolate 2

Positive Cocci

Kocuria rhizophila

Isolate 1

Positive Rod

Bacillus subtilis

Isolate 2

Negative Rod

Pseudomonas fluorescens

Isolate 3

Positive Rod

Bacillus licheniformis

Antimicrobial Disk and Well Diffusion Assays
On both the antimicrobial disk and well diffusion assays, no zones of inhibition
were noted against either Staphylococcus aureus (ATCC 25909) or Escherichia coli
(ATCC 25922). For the positive control, 70% ethanol in water was used. This indicated
no antimicrobial activity from the dried dairy supplements. This is in contradiction to
claims purported by colostrum manufacturers concerning antimicrobial activity
(Symbiotics©, 2010, Nutraceutical Corporation©, 2010 FoodScienceCorp©, 2010) and,
in previous research studies (Pakkanen et al., 1997, Thapa, 2005, Tzipori et al., 1986,
Sarkar et al., 1998, Bitzan et al., 1998, Huppertz et al., 1999, Reiter et al., 1976 Siragusa
and Johnson, 1989, Kamau et al., 1990, Gaya et al., 1991, Thomas et al, 1976, Kamau et
al., 1990, Solomons, 2002).

Previous studies in vivo and in vitro have reported

antimicrobial activity of bovine colostrum against E. coli, Salmonella, Streptococcus,
Staphylococcus, Listeria, Clostridium, H. pylori, rotavirus, and Crytosporidium
(Pakkanen et al., 1997; Thapa, 2005; Tzipori et al., 1986; Sarkar et al., 1998; Bitzan et
al., 1998; Huppertz et al., 1999; Reiter et al., 1976; Siragusa and Johnson, 1989; Kamau

50

et al., 1990; Gaya et al., 1991; Thomas et al, 1976; and Solomons, 2002). Additionally,
bovine colostrum was reported to contain immunoglobulins that can prevent viral
infections, bacterial infections, allergies, yeast, and fungus (Thapa, 2005). However,
many of the reported studies did not utilize dried commercial colostrum supplements.
Hyperimmune colostrum was also used in many of the studies. Hyperimmune bovine
colostrum is harvested post-partum from cows that have been inoculated repeatedly with
specific pathogens during pregnancy.

Therefore, high levels of antibodies or

immunoglobulins can develop against specific pathogens (Pakkanen et al., 1997).
Lactoferrin, lactoperoxidase, growth factors, and other antimicrobials are present in
bovine colostrum.

However, Elfstrand et al. (2002) and Chelack et al. (1993)

demonstrated the reductions of functionality of bovine colostrum bioactive components
post-processing. The antimicrobial activity of the tested dried dairy dietary supplements
examined may have been negatively influenced potentially by processing, as indicated by
the results.
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CONCLUSIONS

Dried dairy dietary supplements, specifically bovine colostrum and whey
products, are readily available in health-food stores for human consumption. Their
manufacturing is regulated only by the food hygiene standards and the Dietary
Supplement Health Education Act of 1994. However, the results of this study indicate
that some of the dried dairy dietary supplements did not adhere to content label claims
concerning fat content, antimicrobial activity and immunoglobulin levels. Bacterial
enumeration of dried colostrum products was difficult due to the inability to distinguish
product particles from colonies. Examination of the bacterial content with 16S rRNA
sequencing analysis of the dried dairy nutraceutical products indicated the presence of
primarily Bacillus and Pseudomonas species.

Additionally, members of the Kocuria,

Microbacterium, and Enterococcus species were identified as well. The presence of
these particular bacterial strains could reveal inconsistencies in the processing and
packaging of these nutraceutical products because each should be destroyed via thermal
processing. Hayden et al. (2007) claimed the leniency of FDA regulations related to
nutraceuticals and dietary supplements has allowed for significant scientific claims to be
presented without the necessary research to support those claims. As with bovine
colostrum dietary supplements, most evidence supporting the effectiveness of
nutraceutical and dietary supplementary are anecdotal (Hayden et al., 2007). The results
of this study indicate label claims are not supported for fat, immunoglobulin content, and
antimicrobial activity versus Escherichia coli (ATCC 25909) and Staphylococcus aureus
(ATCC 25922).
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